- CureToday.com
- OncLive.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Leah Lawrence | Authors
Articles
Subcutaneous Rituximab Maintained Efficacy, Was Safe in DLBCL, FL
October 09, 2019
Switching from intravenous to subcutaneous administration of rituximab for non-Hodgkin diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) resulted in similar efficacy with no new safety issues.
Optimal Treatment for Early-Stage Follicular Lymphoma Still Not Established
October 09, 2019
The international retrospective study included 365 patients with newly diagnosed early-stage follicular lymphoma rigorously staged with PET-CT and bone marrow biopsy.
Social Media Recruiting for Trials Falls Short
October 08, 2019
A survey of physicians found recruiting for trials through social media can be useful, but not for cancer therapeutic trials.
Potency of CAR T-Cell Therapy for Myeloma May Vary by Disease Stage
October 07, 2019
CAR T cells are a more effective therapy if manufactured for patients with multiple myeloma prior to the onset of relapsed or refractory disease.
Transplant Outcomes in Myeloma with Renal Insufficiency Improved
October 07, 2019
Autologous stem cell transplant has become safer over the years for patients with multiple myeloma and renal insufficiency.
PD-L1 Inhibition Plus Pegilodecakin Active in Advanced Solid Tumor All-Comers
October 03, 2019
A combination of pegilodecakin (pegylated IL-10) with an anti-PD-L1 monoclonal antibody inhibitor showed preliminary antitumor activity.
Oncologists Responsive to FDA Label Restrictions
October 01, 2019
After the FDA restricted the labels of 2 drugs used to treat bladder cancer, oncologists' use of these treatments decreased drastically.
Two Studies Confirm OS Benefit of CDK4/6 Inhibitors in Breast Cancer
September 30, 2019
Two studies from ESMO have potentially found treatments which can improve survival in HR-positive breast cancer.
Pembrolizumab Plus Chemo Boosts Response in Triple-Negative Breast Cancer
September 30, 2019
Adding the immunotherapy pembrolizumab to neoadjuvant chemotherapy improved the pathological complete response rate in patients with early triple-negative breast cancer, according to findings of a study presented at ESMO.
MYC-Rearrangement Affects Prognosis 2 Years Post-DLBCL Diagnosis
September 24, 2019
MYC-rearrangement within 2 years after diagnosis may affect the prognosis of patients with diffuse large B-cell lymphoma.